Marie-Eve Beaulieu and Laura Soucek, co-founders of Peptomyc, were the protagonists of the last Dinars de Futur held on Tuesday, October 1 and which, once again, brought together around fifty young entrepreneurs who were attentive to the story that Marie-Eve and Laura had to tell us.
In the biotechnological landscape, they have set out to revolutionize oncology with their emerging company, Pectomyc. Founded around the Vall d’Hebron Hospital, this spin-off seeks to slow the action of the myc protein, one of the main factors responsible for the progression of cancer and present in 70% of tumors.
Laura Soucek admits that she felt that “something in the perfection of nature was missing when I learned about cancer”. Driven by her curiosity and commitment to science, she focused on how to stop myc, a protein that normally helps with cell division and healing, but which in cancer acts out of control. “Myc had to form a partner with another protein called max to function properly, it’s the only way that myc has a single shape”, explains Laura. The study consists of creating an artificial myc to obtain a template that allows the protein to be controlled. Marie-Eve Beaulieu, an expert in structural biology, joined the cause, helping to purify the molecules needed to develop the breakthrough drug, OMO-103, which blocks this protein, offering new hope for patients with solid tumors.
Marie-Eve Beaulieu and Laura Soucek, co-founders of Peptomyc, were the protagonists of the last Dinars de Futur held on Tuesday, October 1 and which, once again, brought together around fifty young entrepreneurs who were attentive to the story that Marie- Eve and Laura had to tell us.
In the biotechnological landscape, they have set out to revolutionize oncology with their emerging company, Pectomyc. Founded around the Vall d’Hebron Hospital, this spin-off seeks to slow the action of the myc protein, one of the main factors responsible for the progression of cancer and present in 70% of tumors.
Laura Soucek admits that she felt that “something in the perfection of nature was missing when I learned about cancer”. Driven by her curiosity and commitment to science, she focused on how to stop myc, a protein that normally helps with cell division and healing, but which in cancer acts out of control. “Myc had to form a partner with another protein called max to function properly, it’s the only way that myc has a single shape”, explains Laura. The study consists of creating an artificial myc to obtain a template that allows the protein to be controlled. Marie-Eve Beaulieu, an expert in structural biology, joined the cause, helping to purify the molecules needed to develop the breakthrough drug, OMO-103, which blocks this protein, offering new hope for patients with solid tumors.
Marie-Eve and Laura ended their talk with a round of questions in which they underlined the need for more financial resources to bring their drug to market and reach a greater number of patients.